KALV PE Ratio & Valuation,Is KALV Overvalued

KALV Relative Valuation

KALV's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, KALV is overvalued; if below, it's undervalued.

Historical Valuation

Kalvista Pharmaceuticals Inc (KALV) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -4.04. The fair price of Kalvista Pharmaceuticals Inc (KALV) is between NaN to NaN according to relative valuation methord.

Relative Value

Fair Zone

NaN-NaN

Current Price：16.90

Fair

-4.25

-4.20

EV/EBITDA

Kalvista Pharmaceuticals Inc. (KALV) has a current EV/EBITDA of -4.20. The 5-year average EV/EBITDA is -0.51. The thresholds are as follows: Strongly Undervalued below -2.62, Undervalued between -2.62 and -1.56, Fairly Valued between 0.55 and -1.56, Overvalued between 0.55 and 1.60, and Strongly Overvalued above 1.60. The current Forward EV/EBITDA of -4.20 falls within the Strongly Undervalued range.

-4.14

EV/EBIT

Kalvista Pharmaceuticals Inc. (KALV) has a current EV/EBIT of -4.14. The 5-year average EV/EBIT is -2.38. The thresholds are as follows: Strongly Undervalued below -6.34, Undervalued between -6.34 and -4.36, Fairly Valued between -0.39 and -4.36, Overvalued between -0.39 and 1.59, and Strongly Overvalued above 1.59. The current Forward EV/EBIT of -4.14 falls within the Historic Trend Line -Fairly Valued range.

13.04

Kalvista Pharmaceuticals Inc. (KALV) has a current PS of 13.04. The 5-year average PS is 165.35. The thresholds are as follows: Strongly Undervalued below -891.14, Undervalued between -891.14 and -362.89, Fairly Valued between 693.60 and -362.89, Overvalued between 693.60 and 1221.85, and Strongly Overvalued above 1221.85. The current Forward PS of 13.04 falls within the Historic Trend Line -Fairly Valued range.

-5.51

P/OCF

Kalvista Pharmaceuticals Inc. (KALV) has a current P/OCF of -5.51. The 5-year average P/OCF is -4.63. The thresholds are as follows: Strongly Undervalued below -10.85, Undervalued between -10.85 and -7.74, Fairly Valued between -1.52 and -7.74, Overvalued between -1.52 and 1.59, and Strongly Overvalued above 1.59. The current Forward P/OCF of -5.51 falls within the Historic Trend Line -Fairly Valued range.

-4.47

P/FCF

Kalvista Pharmaceuticals Inc. (KALV) has a current P/FCF of -4.47. The 5-year average P/FCF is -3.81. The thresholds are as follows: Strongly Undervalued below -7.88, Undervalued between -7.88 and -5.85, Fairly Valued between -1.78 and -5.85, Overvalued between -1.78 and 0.25, and Strongly Overvalued above 0.25. The current Forward P/FCF of -4.47 falls within the Historic Trend Line -Fairly Valued range.

Kalvista Pharmaceuticals Inc (KALV) has a current Price-to-Book (P/B) ratio of 20.86. Compared to its 3-year average P/B ratio of 4.71 , the current P/B ratio is approximately 342.44% higher. Relative to its 5-year average P/B ratio of 3.93, the current P/B ratio is about 430.88% higher. Kalvista Pharmaceuticals Inc (KALV) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -23.67%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -22.43% , the current FCF yield is about -100.00% lower.

19.62

P/B

Median3y

4.71

Median5y

3.93

-19.65

FCF Yield

Median3y

-23.67

Median5y

-22.43

Competitors Valuation Multiple

The average P/S ratio for KALV's competitors is 0.00, providing a benchmark for relative valuation. Kalvista Pharmaceuticals Inc Corp (KALV) exhibits a P/S ratio of , which is NaN% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

Revenue Growth

Market Cap

Performance Decomposition

Market capitalization of KALV increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00%to the performance.

Overall, the performance of KALV in the past 1 year is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is Kalvista Pharmaceuticals Inc (KALV) currently overvalued or undervalued?

What is Kalvista Pharmaceuticals Inc (KALV) fair value?

KALV's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Kalvista Pharmaceuticals Inc (KALV) is between NaN to NaN according to relative valuation methord.

How does KALV's valuation metrics compare to the industry average?

What is the current P/B ratio for Kalvista Pharmaceuticals Inc (KALV) as of Dec 17 2025?

As of Dec 17 2025, Kalvista Pharmaceuticals Inc (KALV) has a P/B ratio of 20.86. This indicates that the market values KALV at 20.86 times its book value.

What is the current FCF Yield for Kalvista Pharmaceuticals Inc (KALV) as of Dec 17 2025?

As of Dec 17 2025, Kalvista Pharmaceuticals Inc (KALV) has a FCF Yield of 0.00%. This means that for every dollar of Kalvista Pharmaceuticals Inc’s market capitalization, the company generates 0.00 cents in free cash flow.

What is the current Forward P/E ratio for Kalvista Pharmaceuticals Inc (KALV) as of Dec 17 2025?

As of Dec 17 2025, Kalvista Pharmaceuticals Inc (KALV) has a Forward P/E ratio of -4.52. This means the market is willing to pay $-4.52 for every dollar of Kalvista Pharmaceuticals Inc’s expected earnings over the next 12 months.

What is the current Forward P/S ratio for Kalvista Pharmaceuticals Inc (KALV) as of Dec 17 2025?

As of Dec 17 2025, Kalvista Pharmaceuticals Inc (KALV) has a Forward P/S ratio of 0.00. This means the market is valuing KALV at $0.00 for every dollar of expected revenue over the next 12 months.

KALV Valuation